Agenda

• Examining how personalized cancer vaccines generate broad and durable tumor specific immune responses, drawing on findings from the intismeran clinical program
• Discussing how emerging translational insights are deepening our understanding of personalized cancer vaccine biology and informing the future development of this therapeutic approach

• Reviewing clinical data in advanced liver cancer and adjuvant GBM patients demonstrating the safety, immunogenicity, and efficacy of Geneos’ personalized vaccine platform
• Exploring how patient-specific neoantigen targeting can enhance anti-tumor immunity across multiple solid tumor indications
• Discussing the implications of these findings for personalized cancer vaccines in advanced and adjuvant cancer treatment settings 

Our dedicated speed networking session is the perfect opportunity to have in-depth conversations and forge long-lasting connections with fellow experts working within Personalized Cancer Vaccines.

• Short-term autologous cancer cell cultures enriched for tumour-initiating cells may be a better source of patient-specific antigens than whole tumour or neo-antigen prediction models
• Antigen presentation by autologous dendritic cells provides some advantages over other means of antigen presentation
• Feasibility, safety, and suggestion of efficacy of such patient-specific vaccines have documented in several cancers

• Evaluating dendritic cell vaccine platforms against RNA, peptide and viral vector based approaches to select the most clinically relevant approach
• Highlighting molecular and cellular features of effective dendritic cell vaccines, including overcoming challenges with abnormal differentiation
• Uncovering strategies for preventing cancer recurrence and improving treatments for the patients in need

• Phase 1 study of a viral-vectored individualized neoantigen vaccine in HNSCC
• Dive deeper into the mutational landscape of the patient population and factors influencing vaccine composition
• Immunogenicity of vaccine neoantigens and potential validation of bioinformatic prediction approach

• Why immune state matters: How prior therapy, disease biology, and immune competence influence the magnitude, quality, and durability of responses to personalized mRNA cancer vaccines
• Building the operating system: An end-to-end clinical and computational platform integrating patient identification, sequencing, vaccine design, manufacturing, regulatory execution, immune monitoring, and longitudinal clinical follow-up
• Learning from every patient: Using standardized, longitudinal clinical and immunologic data to continuously improve antigen selection, vaccine design, treatment strategies, and future personalized mRNA cancer vaccines

Contribute to the conversation and share your cutting-edge research with like-minded PCV experts. To present a poster, register your place and submit an abstract highlighting your breakthroughs. *Please visit the website for T&Cs for presenting a poster

• Which patient populations and disease settings offer the greatest opportunity to demonstrate the value of personalized cancer vaccines in clinical development?
• How should developers balance efficacy, durability, toxicity, and operational complexity when designing combination regimens?
• What manufacturing innovations and regulatory strategies are needed to consistently deliver individualized therapies at scale?

• We have developed SeqCureNEO to make a T-cell therapy with full control over specificity, potency and therapeutic dose
• Currently cancer vaccines have only shown promise in the setting of minimal residual disease and vaccine responses are commonly only seen to a few of the neoantigen epitopes
• We propose combining SeqCureNEO with a cancer vaccine based on the same neoepitopes. Why such a combination would create more potent clinical responses will be discussed in the talk

• Limited impact of immunotherapy on metastatic prostate cancer
• Key need to combine multiple immunotherapy mechanisms to overcome tumor resistance to the immune system
• Using a local-regional approach SYNC-T therapy allows multiple mechanisms to be combined without severe autoimmunity